Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients

Oncology Letters

Volumn 2, Issue 2, 2011, Pages 253-256

  Masago, Katsuhiro ^a   Fujita, Shiro ^b   Togashi, Yosuke ^a   Irisa, Kaoru ^a   Sakamori, Yuichi ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Nagai, Hiroki ^a   Kim, Young Hak ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Brain natriuretic peptide; Metastases; Non small cell lung cancer; Prognostic factor

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SURVIVAL TIME;

EID: 79551630974     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.247     Document Type: Article

References (17)

1. Gardner DG, Chen S, Glenn DJ and Grigsby CL: Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 49: 419-426, 2007.
2. Gardner DG, Kovacic-Milivojevic BK and Garmai M: Atrial natriuretic peptides. In: Molecular Biology of the Natriuretic Peptides. Vesely DL (ed). Research Signpost, Trivandrum, pp15-38, 1977.
3. Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 53: 153-159, 2002.
4. Vesely DL: Natriuretic hormones. In: The Kidney: Physiology and Pathophysiology. 4th edition. Alpern RJ (ed). Elsevier/ Academic Press, San Diego, CA, 2006.
5. Vesely DL: Metabolic targets of cardiac hormones' therapeutic anti-cancer effects. Curr Pharm Des 16: 1159-1166, 2010.
6. Burnett JC Jr, Kao PC, Hu DC, et al: Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231: 1145-1147, 1986.
7. Yoshimura M, Yasue H, Okumura K, et al: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87: 464-469, 1993.
8. Cowie MR, Struthers AD, Wood DA, et al: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350: 1349-1353, 1997.
9. Vesely BA, Song S, Sanchez-Ramos J, et al: Five cardiac hormones decrease the number of human small-cell lung cancer cells. Eur J Clin Invest 35: 388-398, 2005.
10. Vesely BA, Song S, Sanchez-Ramos J, et al: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005.
11. Vesely BA, McAfee Q, Gower WR Jr and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003.
12. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J and Gower WR Jr: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 34: 674-682, 2004.
13. Vesely BA, Fitz SR, Gower WR Jr and Vesely DL: Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells. Cancer Lett 233: 226-231, 2006.
14. Kapoun AM, Liang F, O'Young G, et al: B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94: 453-461, 2004.
15. Bierie B and Moses HL: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21: 49-59, 2010.
16. Tian M and Schiemann WP: The TGF-beta paradox in human cancer: an update. Future Oncol 5: 259-271, 2009.
17. Shmilovich H, Ben-Shoshan J, Tal R, et al: B-type natriuretic peptide enhances vasculogenesis by promoting number and functional properties of early endothelial progenitor cells. Tissue Eng Part A 15: 2741-2749, 2009.